Treatment | AST (lU/l) | ALT (lU/l) | Alph (lU/l) | Bilirubin (g/dl) | Urea mg/dl | Creatinine mg/dl |
---|---|---|---|---|---|---|
Normal control | 47.40 ± 0.92f | 51.20 ± 0.86g | 153.91 ± 0.79h | 0.28 ± 0.01d | 22.93 ± 0.37g | 0.623 ± 0.01d |
Control oil treatment | 47.20 ± 0.86f | 50.80 ± 0.86g | 153.43 ± 0.87h | 0.27 ± 0.01d | 21.04 ± 0.40g | 0.625v0.01d |
Bisphenol A (BPA) | 81.00 ± 1.22a | 101.40 ± 1.72a | 415.99 ± 5.02a | 1.33 ± 0.1a | 54.82 ± 0.48a | 1.27 ± 0.06a |
Protective low dose of FCE | 52.00 ± 0.70c | 62.80 ± 0.86c | 213.06 ± 2.17e | 0.36v0.01bcd | 28.96 ± 0.38d | 0.719 ± 0.01bc |
Protective medium dose of FCE | 58.20 ± 1.39g | 61.00 ± 0.70ef | 199.43 ± 1.79f | 0.34 ± 0.01cd | 27.52 ± 0.28e | 0.719 ± 0.17bc |
Protective high dose of FCE | 55.00 ± 0.70c | 58.60 ± 0.51f | 187.37 ± 1.18g | 0.31 ± 0.01cd | 25.63 ± 0.50f | 0.68 ± 0.005cd |
Therapeutic low dose of FCE | 69.00 ± 0.70b | 73.80 ± 0.58b | 243.87 ± 4.72b | 0.45 ± 0.14b | 34.11 ± 0.35b | 0.783 ± 0.01b |
Therapeutic medium dose of FCE | 68.00 ± 0.94b | 70.60 ± 0.51c | 234.27 ± 2.40c | 0.41 ± 0.01bc | 31.90 ± 0.50c | 0.758 ± 0.01bc |
Therapeutic high dose of FCE | 64.00 ± 0.70c | 67.20 ± 0.86d | 223.23 ± 1.93d | 0.39 ± 0.01bc | 30.88 ± 0.39c | 0.737 ± 0.01bc |